Items where authors include "Crabb, S."
Article
Rescigno, P., Porta, N., Finneran, L. et al. (26 more authors) (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205. 114103. ISSN 0959-8049
Griffin, J. orcid.org/0000-0003-3969-7637, Down, J., Quayle, L.A. et al. (10 more authors) (2024) Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. The Journal of Pathology: Clinical Research, 10 (2). e12363. ISSN 2056-4538
Critchlow, S. orcid.org/0000-0001-6862-765X, Bullement, A. orcid.org/0000-0001-7091-0972, Crabb, S. orcid.org/0000-0003-3521-9064 et al. (9 more authors) (2023) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694
Fulton, B., Jones, R., Powles, T. et al. (8 more authors) (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21. 344. ISSN 1745-6215
Crabb, S., Danson, S.J., Catto, J.W.F. orcid.org/0000-0003-2787-8828 et al. (12 more authors) (2018) SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. Trials, 19. 216. ISSN 1745-6215
Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534
Proceedings Paper
Critchlow, S., Xiao, Y., Crabb, S. et al. (9 more authors) (2022) POSC4 Modeling health-related outcomes with avelumab as a first-line maintenance treatment following chemotherapy vs. best supportive care (BSC) for patients with locally advanced or metastatic urothelial cancer in the UK. In: Value in Health. Virtual ISPOR Europe 2021, 30 Nov - 03 Dec 2021, Virtual conference. Elsevier BV , S32-S33.